RT Journal Article
T1 Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature.
A1 Rodríguez-Otero, Paula
A1 Mateos, María Victoria
A1 Martínez-López, Joaquín
A1 Hernández, Miguel-Teodoro
A1 Ocio, Enrique M
A1 Rosiñol, Laura
A1 Martínez, Rafael
A1 Teruel, Ana-Isabel
A1 Gutiérrez, Norma C
A1 Bargay, Joan
A1 Bengoechea, Enrique
A1 González, Yolanda
A1 de Oteyza, Jaime Pérez
A1 Gironella, Mercedes
A1 Nuñez-Córdoba, Jorge M
A1 Encinas, Cristina
A1 Martín, Jesús
A1 Cabrera, Carmen
A1 Palomera, Luis
A1 de Arriba, Felipe
A1 Cedena, María Teresa
A1 Puig, Noemí
A1 Oriol, Albert
A1 Paiva, Bruno
A1 Bladé, Joan
A1 Lahuerta, Juan José
A1 San Miguel, Jesús F
AB Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) ≥ 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb ≥ 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years.
YR 2019
FD 2019-03-18
LK http://hdl.handle.net/10668/13730
UL http://hdl.handle.net/10668/13730
LA en
DS RISalud
RD Apr 8, 2025